{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:10:10Z","timestamp":1760184610570,"version":"build-2065373602"},"reference-count":130,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.hoc.2008.07.006","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T09:21:01Z","timestamp":1225185661000},"page":"1007-1035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["New Drugs for the Treatment of Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Luca","family":"Paoluzzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matko","family":"Kalac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen A.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2008.07.006_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics","volume":"26","author":"Kerr","year":"1972","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hoc.2008.07.006_bib2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","article-title":"Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-Myc to immortalize pre-B cells","volume":"335","author":"Vaux","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2008.07.006_bib3","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1126\/science.1470921","article-title":"Prevention of programmed cell death in Caenorhabditis elegans by human BCL-2","volume":"258","author":"Vaux","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.hoc.2008.07.006_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0092-8674(93)90485-9","article-title":"The C. Elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1\u03b2-converting enzyme","volume":"75","author":"Yuan","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2008.07.006_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0092-8674(00)80434-1","article-title":"Cytochrome c and dATP-dependent formation of Apaf-1\/caspase-9 complex initiates an apoptotic protease cascade","volume":"91","author":"Li","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2008.07.006_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","article-title":"Bcl-2 heterodimerizes in vivo with a conserved homolog, BAX, that accelerates programmed cell death","volume":"74","author":"Oltvai","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2008.07.006_bib7","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","article-title":"The Bcl-2 apoptotic switch in cancer development and therapy","volume":"26","author":"Adams","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2008.07.006_bib8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0092-8674(00)00187-2","article-title":"BH3-only proteins-essential initiators of apoptotic cell death","volume":"103","author":"Huang","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2008.07.006_bib9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.275.5302.983","article-title":"Structure of Bcl-XL-BAK peptide complex: recognition between regulators of apoptosis","volume":"275","author":"Sattler","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.hoc.2008.07.006_bib10","first-page":"2528","article-title":"Rationale for Bcl-XL\/Bad peptide complex formation from structure, mutagenesis, and biophysical studies","volume":"9","author":"Petros","year":"2000","journal-title":"Protein Sci"},{"key":"10.1016\/j.hoc.2008.07.006_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1097-2765(01)00320-3","article-title":"BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis","volume":"8","author":"Cheng","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.hoc.2008.07.006_bib12","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1101\/gad.897601","article-title":"BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of BAX and BAK","volume":"15","author":"Zong","year":"2001","journal-title":"Genes Dev"},{"key":"10.1016\/j.hoc.2008.07.006_bib13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1099320","article-title":"The pathophysiology of mitochondrial cell death","volume":"305","author":"Green","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.hoc.2008.07.006_bib14","first-page":"2922","article-title":"The expanding role of mitochondria in apoptosis","volume":"15","author":"Wang","year":"2001","journal-title":"Genes Dev"},{"key":"10.1016\/j.hoc.2008.07.006_bib15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1534-5807(01)00083-1","article-title":"Degenerative disorders caused by Bcl-2 deficiency are prevented by loss of its BH3-only antagonist Bim","volume":"1","author":"Bouillet","year":"2001","journal-title":"Dev Cell"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.006_bib16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2174\/1381612043384880","article-title":"Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: new avenues for cancer chemoprevention and chemotherapy","volume":"10","author":"Pellecchia","year":"2004","journal-title":"Curr Pharm Des"},{"issue":"20","key":"10.1016\/j.hoc.2008.07.006_bib17","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1021\/jm030190z","article-title":"Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte\/leukemia-2 proteins","volume":"46","author":"Kitada","year":"2003","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.006_bib18","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1096\/fj.05-5665fje","article-title":"Gossypol induces BAX\/BAK-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2","volume":"20","author":"Lei","year":"2006","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.006_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1535-7163.13.4.1","article-title":"Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma","volume":"4","author":"Mohammad","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.006_bib20","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1182\/blood-2007-12-129833","article-title":"Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma","volume":"111","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.006_bib21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.chembiol.2004.02.020","article-title":"Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L)","volume":"11","author":"Becattini","year":"2004","journal-title":"Chem Biol"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.006_bib22","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1182\/blood-2007-09-113647","article-title":"Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048)","volume":"111","author":"Kitada","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2008.07.006_bib23","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1021\/jm060460o","article-title":"Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins","volume":"49","author":"Wang","year":"2006","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.hoc.2008.07.006_bib24","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-06-1574","article-title":"Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1","volume":"13","author":"Mohammad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2008.07.006_bib25","first-page":"4521","article-title":"Evaluation of TW-37, a pan Bcl-2 proteins small-molecule inhibitor, against spectrum of human B-cell lines and patient-derived samples","volume":"110","author":"Mohammad","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.hoc.2008.07.006_bib26","first-page":"3119","article-title":"A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Evaluation of two dose regimens","volume":"110","author":"Castro","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.hoc.2008.07.006_bib27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2005.1.226","article-title":"Modulating the Bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer","author":"Shore","year":"2005","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.006_bib28","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","article-title":"The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of BAK","volume":"109","author":"P\u00e9rez-Gal\u00e1n","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.006_bib29","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1182\/blood-2006-10-047951","article-title":"Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma","volume":"109","author":"Trudel","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.006_bib30","first-page":"892","article-title":"A phase I trial of the small molecule pan-Bcl-2 family inhibitor obatoclax mesylate (GX15-070) administered by continuous infusion for up to four days to patients with hematological malignancies","volume":"110","author":"Schimmer","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.hoc.2008.07.006_bib31","first-page":"2654","article-title":"A phase I trial of the small molecule pan-Bcl-2 family inhibitor obatoclax mesylate (GX15-070) administered by 24 hour infusion every 2 weeks to patients with myeloid malignancies and chronic lymphocytic leukemia (CLL)","volume":"108","author":"Borthakur","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7042","key":"10.1016\/j.hoc.2008.07.006_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.006_bib33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via BAK\/BAX if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.006_bib34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","article-title":"BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents","volume":"12","author":"Deng","year":"2007","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.006_bib35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.hoc.2008.07.006_bib36","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/sj.onc.1210028","article-title":"A novel Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma","volume":"26","author":"Chauhan","year":"2007","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.hoc.2008.07.006_bib37","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.leu.2404719","article-title":"ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells","volume":"21","author":"Kline","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.006_bib38","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2007-03-080325","article-title":"Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo","volume":"110","author":"Kang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.006_bib39","doi-asserted-by":"crossref","unstructured":"Paoluzzi L, Gonen M, Bhagat G, et\u00a0al. The BH3-only mimetic ABT-737 synergizes the anti-neoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008 [Epub ahead of print].","DOI":"10.1182\/blood-2007-12-130781"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.006_bib40","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1158\/0008-5472.CAN-06-3964","article-title":"Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing BAK activation and BAX translocation","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.006_bib41","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Del Gaizo Moore","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.006_bib42","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/0008-5472.CAN-06-2203","article-title":"Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737","volume":"67","author":"Tahir","year":"2007","journal-title":"Cancer Res"},{"issue":"27","key":"10.1016\/j.hoc.2008.07.006_bib43","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1038\/sj.onc.1210166","article-title":"\u2018Seed\u2019 analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2\/Bcl-XL inhibitor ABT-737","volume":"26","author":"Lin","year":"2007","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.006_bib44","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1101\/gad.1093903","article-title":"Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation","volume":"17","author":"Nijhawan","year":"2003","journal-title":"Genes Dev"},{"issue":"7","key":"10.1016\/j.hoc.2008.07.006_bib45","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.cell.2005.06.009","article-title":"Mule\/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitylation of Mcl-1 and regulates apoptosis","volume":"121","author":"Zhong","year":"2005","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.006_bib46","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2008.07.006_bib47","first-page":"1371","article-title":"A phase 1\/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies","volume":"110","author":"Wilson","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.hoc.2008.07.006_bib48","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.4049\/jimmunol.166.8.4891","article-title":"Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4","volume":"166","author":"Chuntharapai","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.hoc.2008.07.006_bib49","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/91000","article-title":"Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity","volume":"7","author":"Ichikawa","year":"2001","journal-title":"Nature Med"},{"key":"10.1016\/j.hoc.2008.07.006_bib50","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1084\/jem.20031457","article-title":"Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy","volume":"199","author":"Takeda","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.hoc.2008.07.006_bib51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/1389201023378256","article-title":"Engineering antibodies for therapy","volume":"3","author":"Presta","year":"2002","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.hoc.2008.07.006_bib52","first-page":"489","article-title":"Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed\/refractory non-Hodgkin's lymphoma (NHL)","volume":"106","author":"Younes","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.hoc.2008.07.006_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/pros.20126","article-title":"Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo","volume":"62","author":"Shankar","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.hoc.2008.07.006_bib54","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1038\/sj.cdd.4401535","article-title":"Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies","volume":"11","author":"Inoue","year":"2004","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.hoc.2008.07.006_bib55","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.V98.3.795","article-title":"TRAIL\/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications","volume":"98","author":"Mitsiades","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.006_bib56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.hoc.2008.07.006_bib57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","article-title":"Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety","volume":"299","author":"Kelley","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"6639","key":"10.1016\/j.hoc.2008.07.006_bib58","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/40901","article-title":"X-linked IAP is a direct inhibitor of cell-death proteases","volume":"388","author":"Deveraux","year":"1997","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.hoc.2008.07.006_bib59","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1038\/sj.onc.1202569","article-title":"The inhibitors of apoptosis (IAPs) and their emerging role in cancer","volume":"17","author":"LaCasse","year":"1998","journal-title":"Oncogene"},{"issue":"17","key":"10.1016\/j.hoc.2008.07.006_bib60","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1021\/jm0499108","article-title":"Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein\/caspase-9 interaction site","volume":"47","author":"Sun","year":"2004","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.hoc.2008.07.006_bib61","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1021\/jm040037k","article-title":"Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer","volume":"47","author":"Oost","year":"2004","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.006_bib62","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/jm030420+","article-title":"Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database","volume":"47","author":"Nikolovska-Coleska","year":"2004","journal-title":"J Med Chem"},{"issue":"5689","key":"10.1016\/j.hoc.2008.07.006_bib63","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1126\/science.1098231","article-title":"A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death","volume":"305","author":"Li","year":"2004","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.hoc.2008.07.006_bib64","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat Med"},{"issue":"53","key":"10.1016\/j.hoc.2008.07.006_bib65","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1038\/sj.onc.1207113","article-title":"Survivin, versatile modulation of cell division and apoptosis in cancer","volume":"22","author":"Altieri","year":"2003","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.006_bib66","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1080\/10428190600725354","article-title":"Survivin\u2014an attractive target for RNAi in non-Hodgkin's lymphoma, Daudi cell line as a model","volume":"47","author":"Congmin","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2008.07.006_bib67","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0167-5699(99)01574-1","article-title":"Tyrosine kinase Syk: essential functions for immunoreceptor signaling","volume":"21","author":"Turner","year":"2000","journal-title":"Immunol Today"},{"key":"10.1016\/j.hoc.2008.07.006_bib68","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1126\/science.1071546","article-title":"B cell antigen receptor signaling: roles in cell development and disease","volume":"296","author":"Stephen","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.hoc.2008.07.006_bib69","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B cell lymphomas identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"issue":"6769","key":"10.1016\/j.hoc.2008.07.006_bib70","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2008.07.006_bib71","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2007-07-100115","article-title":"Syk dependent tonic B cell receptor signalling is a rational treatment target in diffuse large B cell lymphoma","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.006_bib72","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1084\/jem.20060967","article-title":"Deregulated Syk inhibits differentiation and induces growth factor- independent proliferation of pre-B cells","volume":"203","author":"Wossning","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.hoc.2008.07.006_bib73","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2005.05883.x","article-title":"Genomic and expression profiling identifies the B cell associated Syk as a possible therapeutic target in mantle cell lymphoma","volume":"132","author":"Rinasldi","year":"2005","journal-title":"Br\u00a0J Haematol"},{"key":"10.1016\/j.hoc.2008.07.006_bib74","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood-2006-05-026203","article-title":"Syk dependent m TOR activation in follicular lymphoma cells","volume":"108","author":"Leseux","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.006_bib75","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.hoc.2008.07.006_bib76","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clim.2007.06.005","article-title":"Syk kinase as a treatment target for therapy\/in autoimmune diseases","volume":"124","author":"Vasileois","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.hoc.2008.07.006_bib77","unstructured":"Friedberg J, Sharman J, Schaefer-Curillo J, et al. Tamatinib fosdium (TAMF), an oral Syk inhibitor, has significant clinical activity in B-cell non-Hodgkin's lymphoma (NHL). 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008."},{"key":"10.1016\/j.hoc.2008.07.006_bib78","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/annonc\/mdi113","article-title":"mTOR-targeted therapy of cancer with rapamycin derivatives","volume":"16","author":"Vignot","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2008.07.006_bib79","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1038\/sj.onc.1209091","article-title":"Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3\u2032 kinase\/AKT pathways","volume":"24","author":"Larue","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2008.07.006_bib80","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1432-1327.1999.00120.x","article-title":"Protein kinase C","volume":"259","author":"Gschwendt","year":"1999","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.hoc.2008.07.006_bib81","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/BJ20040704","article-title":"Distinctive activation mechanisms and functions for protein kinase C","volume":"384","author":"Steinberg","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.hoc.2008.07.006_bib82","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S1470-2045(05)70168-6","article-title":"The MAPK signalling pathways and colorectal cancer","volume":"6","author":"Fang","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2008.07.006_bib83","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","article-title":"The Akt-mTOR tango and its relevance to cancer","volume":"8","author":"Hay","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2008.07.006_bib84","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.cdd.4400978","article-title":"Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic","volume":"9","author":"Castedo","year":"2002","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.hoc.2008.07.006_bib85","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0955-0674(97)80078-6","article-title":"TOR signaling and control of control of cell growth","volume":"9","author":"Thomas","year":"1997","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.hoc.2008.07.006_bib86","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2008.07.006_bib87","doi-asserted-by":"crossref","first-page":"7772","DOI":"10.1073\/pnas.95.13.7772","article-title":"Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway","volume":"95","author":"Scott","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hoc.2008.07.006_bib88","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1042\/bj3440427","article-title":"Mammalian target of rapamycin is\u00a0a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation","volume":"344","author":"Nave","year":"1999","journal-title":"Biochem J"},{"key":"10.1016\/j.hoc.2008.07.006_bib89","doi-asserted-by":"crossref","first-page":"9267","DOI":"10.1073\/pnas.89.19.9267","article-title":"Akt2, a putative oncogene encoding a member of a subfamily of serine\/threonine kinases, is amplified in human ovarian carcinomas","volume":"89","author":"Cheng","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hoc.2008.07.006_bib90","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1073\/pnas.93.8.3636","article-title":"Amplification of AKT 2 in human pancreatic cells and inhibition of Akt 2 expression and tumorigenicity by antisense RNA","volume":"93","author":"Cheng","year":"1996","journal-title":"Proc Natl Acad Sci U\u00a0S A"},{"key":"10.1016\/j.hoc.2008.07.006_bib91","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ijc.2910640412","article-title":"Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas","volume":"64","author":"Bellacosa","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hoc.2008.07.006_bib92","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hoc.2008.07.006_bib93","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/370527a0","article-title":"Phosphatidylinositol-3-OH kinase as a direct target of Ras","volume":"370","author":"Rodriguez-Viciana","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2008.07.006_bib94","doi-asserted-by":"crossref","first-page":"8204","DOI":"10.1073\/pnas.0502857102","article-title":"The coordinate regulation of the p53 and mTOR pathways in cells","volume":"102","author":"Feng","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.006_bib95","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. Taxonomy of the producing streptomycete and isolation of the active principle. I","volume":"28","author":"Vezina","year":"1975","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.hoc.2008.07.006_bib96","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.hoc.2008.07.006_bib97","doi-asserted-by":"crossref","first-page":"31824","DOI":"10.1074\/jbc.271.50.31824","article-title":"Inhibition of the phosphatidylinositol 3-kinase\/p70(S6)-kinase pathway induces B16 melanoma cell differentiation","volume":"271","author":"Busca","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hoc.2008.07.006_bib98","first-page":"3581","article-title":"Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP\u2013p70s6K pathway in human pancreatic cancer cells","volume":"59","author":"Grewe","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2008.07.006_bib99","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1096\/fj.01-0658com","article-title":"Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling","volume":"16","author":"Humar","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.hoc.2008.07.006_bib100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2005-06-2208","article-title":"Pro-angiogenic stimulation of bone marrow endothelium engages mTOR, and is inhibited by simultaneous blockade of mTOR and NF-B","volume":"107","author":"Costa","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.006_bib101","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1093\/emboj\/cdf391","article-title":"Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope","volume":"21","author":"Castedo","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.hoc.2008.07.006_bib102","first-page":"62","article-title":"Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents","volume":"57","author":"Decaudin","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2008.07.006_bib103","first-page":"2547","article-title":"A novel bispecific antisense oligonucleotide inhibiting both BCL-2 and BCL-XL expression efficiently induces apoptosis in tumor cells","volume":"6","author":"Zangemeister-Wittke","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2008.07.006_bib104","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1128\/MCB.21.3.854-864.2001","article-title":"Down regulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors","volume":"21","author":"Shinjyo","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.hoc.2008.07.006_bib105","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1111\/j.1742-4658.2005.04833.x","article-title":"Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain","volume":"272","author":"Li","year":"2005","journal-title":"FEBS J"},{"key":"10.1016\/j.hoc.2008.07.006_bib106","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nrc1738","article-title":"Lysosomes and autophagy in cell death control","volume":"11","author":"Kroemer","year":"2005","journal-title":"Nature Rev Cancer"},{"key":"10.1016\/j.hoc.2008.07.006_bib107","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1017\/S1462399408000586","article-title":"Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas","volume":"10","author":"Drakos","year":"2008","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.hoc.2008.07.006_bib108","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"16","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.006_bib109","first-page":"A726","article-title":"CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study","volume":"19","author":"Hidalgo","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.006_bib110","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O'Donnell","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.006_bib111","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies","volume":"26","author":"Mita","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.006_bib112","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2008.07.006_bib113","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.006_bib114","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2008.07.006_bib115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/120347540200600203","article-title":"Transformation in mycosis fungoides: the role of methotrexate","volume":"6","author":"Abd-el-Baki","year":"2002","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.hoc.2008.07.006_bib116","first-page":"551","article-title":"New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice","volume":"69","author":"Schmid","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.hoc.2008.07.006_bib117","first-page":"18","article-title":"New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties","volume":"12","author":"Sirotnak","year":"1984","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hoc.2008.07.006_bib118","first-page":"26","article-title":"New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models","volume":"12","author":"Sirotnak","year":"1984","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hoc.2008.07.006_bib119","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1078-0432.CCR-05-0331","article-title":"The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma","volume":"12","author":"Toner","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2008.07.006_bib120","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.006_bib121","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","article-title":"Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier type-1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma","volume":"139","author":"O'Connor","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2008.07.006_bib122","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orallyt available spleen tyrosine kinase inhibitor blocks receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.006_bib123","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.taap.2007.03.027","article-title":"Immunotoxicity assessment for the novel spleen tyrosine kinase inhibitor R406","volume":"221","author":"Zhu","year":"2007","journal-title":"Toxicol Appl Pharmacol"},{"issue":"13","key":"10.1016\/j.hoc.2008.07.006_bib124","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1084\/jem.20060967","article-title":"Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells","volume":"203","author":"Wossning","year":"2006","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.006_bib125","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2007-07-100115","article-title":"Syk-dependent tonic B-cell receptor signaling is a rationL treatment target in diffuse large B-cell lymphoma","volume":"111","author":"Wossning","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2008.07.006_bib126","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.bcp.2006.12.010","article-title":"Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines","volume":"73","author":"Aggarwal","year":"2007","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.006_bib127","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ijc.23477","article-title":"Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-\u03baB and STST3 pathways in Hodgkin's lymphoma cells","volume":"123","author":"Mackenzie","year":"2008","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.006_bib128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.178.1.111","article-title":"Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth","volume":"178","author":"Gururajan","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.hoc.2008.07.006_bib129","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.90644.2007","article-title":"Platelets undergo phosphorylation of Syk at Y525\/526 and Y352 in response to pathophysiological shear stress","author":"Speich","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.006_bib130","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejphar.2007.11.009","article-title":"Evaluation of [3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihydro-1H-indole-5-sulfonamide] (OXSI-2), as a Syk-selective inhibitor in platelets","volume":"580","author":"Bhavaraju","year":"2008","journal-title":"Eur J Pharmacol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858808001020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858808001020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:51:35Z","timestamp":1760183495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858808001020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":130,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0889858808001020"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2008.07.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Drugs for the Treatment of Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2008.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}